In Reply The 2.0 to 2.5 odds ratio for renal cancer for different CHEK2 variants reported by Zlowocka-Perlowska and colleagues in their letter closely approximates our pooled analysis that showed an odds ratio of 3.0 (95% CI, 1.3-5.8).1 Of note, Zlowocka-Perlowska et al have found a single CHEK2 founder mutation (I157T) in a striking 9.3% of renal cancer cases in Poland thus far, but they describe the risk for this mutation as being similar to other truncating CHEK2 mutations. With tumor-normal genotyping now being conducted across multiple cancer types to guide preventive care and target therapies,2 population-specific variant–level analysis such as the analysis performed by Zlowocka-Perlowska et al will facilitate more precise cancer risk estimates.
Carlo MI, Mukherjee S, Offit K. CHEK2 Alleles Predispose to Renal Cancer in Poland—In Reply. JAMA Oncol. 2019;5(4):576–577. doi:10.1001/jamaoncol.2019.0025
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: